Amylin Pharmaceuticals, Inc. (AMLN) Posts Q3 Loss of $0.07, Sales Fall Short
Get Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $155.1 million versus the consensus estimate of $166.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- China Automotive Systems (CAAS) Tops Q4 EPS by 24c ; Offers Guidance
- Carnival Corp. (CCL) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!